265 related articles for article (PubMed ID: 25284489)
1. Therapy-related myelodysplastic syndrome/acute leukemia after multiple myeloma in the era of novel agents.
Gertz MA; Terpos E; Dispenzieri A; Kumar S; Shah RA; Orlowski R; Kastritis E; Dimopoulos MA; Shah J
Leuk Lymphoma; 2015 Jun; 56(6):1723-6. PubMed ID: 25284489
[TBL] [Abstract][Full Text] [Related]
2. [Impacts of new agents for multiple myeloma on development of secondary myelodysplastic syndrome and acute myeloid leukemia].
Hamano A; Shingaki S; Abe Y; Miyazaki K; Sekine R; Nakagawa Y; Tsukada N; Hattori Y; Suzuki K
Rinsho Ketsueki; 2014 Apr; 55(4):428-35. PubMed ID: 24850453
[TBL] [Abstract][Full Text] [Related]
3. Characteristics and Outcomes of Patients With Multiple Myeloma Who Developed Therapy-Related Acute Myeloid Leukemia and Myelodysplastic Syndrome After Autologous Cell Transplantation.
Yalniz FF; Greenbaum U; Pasvolsky O; Milton DR; Kanagal-Shamanna R; Ramdial J; Srour S; Mehta R; Alousi A; Popat UR; Nieto Y; Kebriaei P; Al-Atrash G; Oran B; Hosing C; Ahmed S; Champlin RE; Shpall EJ; Qazilbash MH; Bashir Q
Transplant Cell Ther; 2024 Feb; 30(2):205.e1-205.e12. PubMed ID: 37437764
[TBL] [Abstract][Full Text] [Related]
4. Thalidomide paradoxical effect on concomitant multiple myeloma and myelodysplasia.
Badros A; Morris C; Zangari M; Barlogie B; Tricot G
Leuk Lymphoma; 2002 Jun; 43(6):1267-71. PubMed ID: 12152995
[TBL] [Abstract][Full Text] [Related]
5. Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma.
Usmani SZ; Sawyer J; Rosenthal A; Cottler-Fox M; Epstein J; Yaccoby S; Sexton R; Hoering A; Singh Z; Heuck CJ; Waheed S; Chauhan N; Johann D; Abdallah AO; Muzaffar J; Petty N; Bailey C; Crowley J; van Rhee F; Barlogie B
Blood; 2013 Jun; 121(23):4753-7. PubMed ID: 23603914
[TBL] [Abstract][Full Text] [Related]
6. Longitudinal bone marrow evaluations for myelodysplasia in patients with myeloma before and after treatment with lenalidomide.
Monaghan SA; Dai L; Mapara MY; Normolle DP; Gollin SM; Lentzsch S
Leuk Lymphoma; 2013 Sep; 54(9):1965-74. PubMed ID: 23216269
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
[TBL] [Abstract][Full Text] [Related]
8. Lenalidomide in myelodysplastic syndrome and multiple myeloma.
Shah SR; Tran TM
Drugs; 2007; 67(13):1869-81. PubMed ID: 17722955
[TBL] [Abstract][Full Text] [Related]
9. Acute lymphoblastic leukemia developing during maintenance therapy with lenalidomide in a patient with multiple myeloma.
García-Muñoz R; Robles-de-Castro D; Muñoz-Rodríguez A; Rabasa P
Leuk Lymphoma; 2013 Dec; 54(12):2753-5. PubMed ID: 23488662
[No Abstract] [Full Text] [Related]
10. Characteristics and outcomes of patients with multiple myeloma who develop therapy-related myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia.
Pemmaraju N; Shah D; Kantarjian H; Orlowski RZ; Nogueras González GM; Baladandayuthapani V; Jain N; Wagner V; Garcia-Manero G; Shah J; Ravandi F; Pierce S; Takahashi K; Daver N; Nazha A; Verstovsek S; Jabbour E; De Lima M; Champlin R; Cortes J; Qazilbash MH
Clin Lymphoma Myeloma Leuk; 2015 Feb; 15(2):110-4. PubMed ID: 25107338
[TBL] [Abstract][Full Text] [Related]
11. The clinical safety of lenalidomide in multiple myeloma and myelodysplastic syndromes.
Palumbo A; Freeman J; Weiss L; Fenaux P
Expert Opin Drug Saf; 2012 Jan; 11(1):107-20. PubMed ID: 22066855
[TBL] [Abstract][Full Text] [Related]
12. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma.
Attal M; Lauwers-Cances V; Marit G; Caillot D; Moreau P; Facon T; Stoppa AM; Hulin C; Benboubker L; Garderet L; Decaux O; Leyvraz S; Vekemans MC; Voillat L; Michallet M; Pegourie B; Dumontet C; Roussel M; Leleu X; Mathiot C; Payen C; Avet-Loiseau H; Harousseau JL;
N Engl J Med; 2012 May; 366(19):1782-91. PubMed ID: 22571202
[TBL] [Abstract][Full Text] [Related]
13. Autologous HSC transplant in t-MDS/AML using cells harvested prior to the development of the secondary malignancy.
Costa LJ; Rodriguez V; Porrata LF; Lacy MQ; Elliott MA; Gertz MA; Gastineau DA; Litzow MR
Bone Marrow Transplant; 2008 Oct; 42(7):497-8. PubMed ID: 18622421
[No Abstract] [Full Text] [Related]
14. Autologous transplantation and maintenance therapy in multiple myeloma.
Palumbo A; Cavallo F; Gay F; Di Raimondo F; Ben Yehuda D; Petrucci MT; Pezzatti S; Caravita T; Cerrato C; Ribakovsky E; Genuardi M; Cafro A; Marcatti M; Catalano L; Offidani M; Carella AM; Zamagni E; Patriarca F; Musto P; Evangelista A; Ciccone G; Omedé P; Crippa C; Corradini P; Nagler A; Boccadoro M; Cavo M
N Engl J Med; 2014 Sep; 371(10):895-905. PubMed ID: 25184862
[TBL] [Abstract][Full Text] [Related]
15. Cumulative exposure to melphalan chemotherapy and subsequent risk of developing acute myeloid leukemia and myelodysplastic syndromes in patients with multiple myeloma.
Jonsdottir G; Björkholm M; Turesson I; Hultcrantz M; Diamond B; Porwit A; Landgren O; Kristinsson SY
Eur J Haematol; 2021 Aug; 107(2):275-282. PubMed ID: 33966293
[TBL] [Abstract][Full Text] [Related]
16. Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy.
Carney DA; Westerman DA; Tam CS; Milner A; Prince HM; Kenealy M; Wolf M; Januszewicz EH; Ritchie D; Came N; Seymour JF
Leukemia; 2010 Dec; 24(12):2056-62. PubMed ID: 20962860
[TBL] [Abstract][Full Text] [Related]
17. Lenalidomide: a review of its continuous use in patients with newly diagnosed multiple myeloma not eligible for stem-cell transplantation.
McCormack PL
Drugs Aging; 2015 May; 32(5):409-18. PubMed ID: 25925941
[TBL] [Abstract][Full Text] [Related]
18. Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome.
Narayan R; Garcia JS; Percival ME; Berube C; Coutre S; Gotlib J; Greenberg P; Liedtke M; Hewitt R; Regan K; Williamson C; Doykan C; Cardone MH; McMillan A; Medeiros BC
Leuk Lymphoma; 2016; 57(3):609-15. PubMed ID: 26374199
[TBL] [Abstract][Full Text] [Related]
19. Lenalidomide in patients with red blood cell transfusion-dependent myelodysplastic syndrome and del(5q): a single-centre "real-world" experience.
Cerqui E; Pelizzari A; Schieppati F; Borlenghi E; Pagani C; Bellotti D; Lamorgese C; Boiocchi L; Sottini A; Imberti L; Rossi G
Leuk Lymphoma; 2015; 56(11):3129-34. PubMed ID: 25811676
[TBL] [Abstract][Full Text] [Related]
20. A review of therapy-related myelodysplastic syndromes and acute myeloid leukaemia (t-MDS/AML) in Irish patients: a single centre experience.
Maung SW; Burke C; Hayde J; Walshe J; McDermott R; Desmond R; McHugh J; Enright H
Hematology; 2017 Jul; 22(6):341-346. PubMed ID: 28196450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
